GB2347742B - Pharmaceutical composition for RBD - Google Patents

Pharmaceutical composition for RBD

Info

Publication number
GB2347742B
GB2347742B GB9928642A GB9928642A GB2347742B GB 2347742 B GB2347742 B GB 2347742B GB 9928642 A GB9928642 A GB 9928642A GB 9928642 A GB9928642 A GB 9928642A GB 2347742 B GB2347742 B GB 2347742B
Authority
GB
United Kingdom
Prior art keywords
rbd
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9928642A
Other versions
GB9928642D0 (en
GB2347742A (en
Inventor
Andrew Jeremy Wakefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ROYAL FREE HOSP SCHOOL MED
Royal Free Hospital School of Medicine
Original Assignee
ROYAL FREE HOSP SCHOOL MED
Royal Free Hospital School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711663.6A external-priority patent/GB9711663D0/en
Priority to GBGB9711663.6A priority Critical patent/GB9711663D0/en
Application filed by ROYAL FREE HOSP SCHOOL MED, Royal Free Hospital School of Medicine filed Critical ROYAL FREE HOSP SCHOOL MED
Priority to GB9926916A priority patent/GB2341551A/en
Publication of GB9928642D0 publication Critical patent/GB9928642D0/en
Publication of GB2347742A publication Critical patent/GB2347742A/en
Publication of GB2347742B publication Critical patent/GB2347742B/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Application status is Expired - Fee Related legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
GB9928642A 1997-06-05 1998-06-04 Pharmaceutical composition for RBD Expired - Fee Related GB2347742B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB9711663.6A GB9711663D0 (en) 1997-06-05 1997-06-05 Pharmaceutical composition for treatment of IBD and RBD
GB9926916A GB2341551A (en) 1997-06-05 1998-06-04 Pharmaceutical composition containing transfer factor for treatment of inflammatory bowel disease and regressive behavioural disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9711663.6A GB9711663D0 (en) 1997-06-05 1997-06-05 Pharmaceutical composition for treatment of IBD and RBD

Publications (3)

Publication Number Publication Date
GB9928642D0 GB9928642D0 (en) 2000-02-02
GB2347742A GB2347742A (en) 2000-09-13
GB2347742B true GB2347742B (en) 2001-11-07

Family

ID=26311660

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9928642A Expired - Fee Related GB2347742B (en) 1997-06-05 1998-06-04 Pharmaceutical composition for RBD

Country Status (1)

Country Link
GB (1) GB2347742B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163278B2 (en) 1999-12-17 2012-04-24 Curemark Llc Methods for treating pervasive development disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
ES2668909T3 (en) 2009-01-06 2018-05-23 Galenagen, Llc Compositions comprising protease, amylase and lipase for use in the treatment of Staphylococcus aureus infections
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101200A2 (en) * 1982-07-20 1984-02-22 BIO-COM Inc. Transfer factor for use in treating viral infections
WO1996030544A1 (en) * 1995-03-28 1996-10-03 Andrew Jeremy Wakefield Diagnostic and therapeutic system for crohn's disease and colitia ulcerosa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101200A2 (en) * 1982-07-20 1984-02-22 BIO-COM Inc. Transfer factor for use in treating viral infections
WO1996030544A1 (en) * 1995-03-28 1996-10-03 Andrew Jeremy Wakefield Diagnostic and therapeutic system for crohn's disease and colitia ulcerosa
GB2300259A (en) * 1995-03-28 1996-10-30 Andrew Jeremy Wakefield Diagnosing Crohn's disease or ulcerative colitis by detection of measles virus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Clin. Microbiol. Vol. 31 (3) 1991. Condorelli F & ZieglerT pages 717-719 *
J. Virol. Methods Vol. 15 1987. Fukuda A et.al. pages 279-284 *
J. Virol. Methods Vol. 27 1990. Umino Y et.al. pages 159-168 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163278B2 (en) 1999-12-17 2012-04-24 Curemark Llc Methods for treating pervasive development disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders

Also Published As

Publication number Publication date
GB9928642D0 (en) 2000-02-02
GB2347742A (en) 2000-09-13

Similar Documents

Publication Publication Date Title
EG24435A (en) Novel pharmaceutical composition
GB2298789B (en) Pharmaceutical compositions
AU733047C (en) Pharmaceutical composition
HRP970100A2 (en) Pharmaceutical composition for immunomodulation
PL196261B1 (en) Aerosol pharmaceutical formulations
GB2288732B (en) Pharmaceutical compositions
SK15182001A3 (en) Pharmaceutical composition for dermal application
HU9802086A3 (en) Pharmaceutical composition for piperidinoalkanol compounds
HK1022652A1 (en) Aqueous-based pharmaceutical composition
HRP20000198A2 (en) Medicaments
ZA9810490B (en) 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
ZA9610792B (en) Stabilized pharmaceutical composition
PL336840A1 (en) Hair-care composition
SK79496A3 (en) Pharmaceutical composition
PL194079B1 (en) Highly active phytases-containing composition
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
SK52197A3 (en) Pharmaceutical compositions
ZA9507247B (en) Pharmaceutical compositions
EP1017379A4 (en) Therapeutic compositions
CY2211B1 (en) Pharmaceutical compositions
GB9700624D0 (en) Drug delivery composition
ZA9502169B (en) Pharmaceutical compositions
IL128765D0 (en) Pharmaceutical compositions containing isoflavones
EG24118A (en) Pharmaceutical compositions
GB9817118D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20080604